Merck on Wednesday said its cancer drug Keytruda helped extend survival as well as prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer.
Keytruda is actually being studied as a as a first-line treatment for metastatic squamous non-smaller cell lung cancer patients. The combination therapy met its main trial goals when compared to patients who were on chemotherapy alone.
Keytruda is actually the only immunotherapy approved inside United States to treat lung cancer patients who have not received prior treatment.
Merck has been expanding its position into the lung cancer market through Keytruda. Also jockeying for a piece of the lucrative market are drugmakers such as Bristol-Myers Squibb , Roche as well as AstraZeneca of which are advancing their rival immunotherapies.Merck said the brand-new data will be shared with the U.S. Food as well as Drug Administration as part of its push to expand the drug’s label.
The data could be presented at an upcoming medical conference, the company said.